|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘 | Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote | 2012 | The Lancet2012，，： | 14 |
| 2 | Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial显示文摘 | Eric Lawitz Fred F Poordad Phillip S Pang Robert H Hyland Xiao Ding Hongmei Mo William T Symonds John G McHutchison Fernando E Membreno | 2013 | The Lancet2013，，： | 5 |
| 3 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | The Lancet2001，，9286： | 4 |
| 4 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial显示文摘 | Manns MP McHutchison JG Gordon SC | | The Lancet0，，： | 4 |
| 5 | FibroSURE^(TM) and FibroScan~ in relation to treatment response in chronic hepatitis C virus显示文摘AIM:To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus(HCV)cohort.METHODS:Patients with chronic HCV were randomized to receive interferon-based therapy for 24(genotypes 2/3)or 48(genotype 1)wk.FibroSURE~TM(FS)was assessed at baseline and at week-12 post-treatment follow-up.Baseline biopsy for METAVIR was assessed by a single pathologist.FibroScan~ transient elastogra-phy(TE)was performed during treatment in a patient subset.RESULTS:Two thousand and sixty patients(n = 253 in Asia)were classif ied as METAVIR F0-1(n = 1682)or F2-4(n = 378).For F2-4,FS(n = 2055)had sensitiv-ity and specif icity of 0.87 and 0.61,respectively,with area under the receiver-operating curve of 0.82;corre-sponding values for TE(n = 214)and combined FS/TE(n = 209)were 0.77,0.88 and 0.88,and 0.93,0.68 and 0.88.Overall FS/TE agreement for F2-4 was 71%(κ = 0.41)and higher in Asians vs non-Asians(κ = 0.86 vs 0.35;P < 0.001).Combined FS/TE had 97% accuracy in Asians(n = 33).Baseline FS(0.38 vs 0.51,P < 0.001)and TE(8.0 kPa vs 11.9 kPa,P = 0.006)scores were lower in patients with sustained virological response than in nonresponders,and were maintained through follow-up.CONCLUSION:FS and TE may reliably differentiate mild from moderate-advanced disease,with a potential for high diagnostic accuracy in Asians with chronic HCV. | Keyur Patel Mireen Friedrich-Rust Yoav Lurie Mircea Grigorescu Carol Stanciu Chuan-Mo Lee Eugene R Schiff Dieter Hussinger Michael P Manns Guido Gerken Isabelle Colle Michael Torbenson Erik Pulkstenis G Mani Subramanian John G McHutchison Stefan Zeuzem | 2011 | World Journal of Gastroenterology2011，17，41： | 4 |
| 6 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | The Lancet . 2001 (9286)2001，，9286： | 4 |
| 7 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial显示文摘 | Michael P Manns John G McHutchison Stuart C Gordon Vinod K Rustgi Mitchell Shiffman Robert Reindollar Zachary D Goodman Kenneth Koury Mei-Hsiu Ling Janice K Albrecht | 2001 | 2001 (9286)2001，，9286： | 4 |
| 8 | Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study显示文摘 | Michael P. Curry Xavier Forns Raymond T. Chung Norah A. Terrault Robert Brown Jonathan M. Fenkel Fredric Gordon Jacqueline O’Leary Alexander Kuo Thomas Schiano Gregory Everson Eugene Schiff Alex Befeler Edward Gane Sammy Saab John G. McHutchison G. Mani S | 2014 | Gastroenterology2014，，： | 3 |
| 9 | O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY显示文摘 | N. Afdhal G. Everson J.L. Calleja G. McCaughan W.T. Symonds J. Denning L. McNair J.G. McHutchison S. Arterburn M. Charlton R. Reddy T. Asselah E. Gane X. Forns | 2014 | Journal of Hepatology2014，，1： | 3 |
| 10 | Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation显示文摘 | Michael Charlton Edward Gane Michael P. Manns Robert S. Brown Michael P. Curry Paul Y. Kwo Robert J. Fontana Richard Gilroy Lewis Teperman Andrew J. Muir John G. McHutchison William T. Symonds Diana Brainard Brian Kirby Hadas Dvory-Sobol Jill Denning Sara | 2014 | Gastroenterology2014，，： | 2 |
| 11 | O6 SOFOSBUVIR/LEDIPASVIR FIXED DOSE COMBINATION IS SAFE AND EFFECTIVE IN DIFFICULT-TO-TREAT POPULATIONS INCLUDING GENOTYPE-3 PATIENTS, DECOMPENSATED GENOTYPE-1 PATIENTS, AND GENOTYPE-1 PATIENTS WITH PRIOR SOFOSBUVIR TREATMENT EXPERIENCE显示文摘 | E.J. Gane R.H. Hyland D. An P.S. Pang W.T. Symonds J.G. Mchutchison C.A. Stedman | 2014 | Journal of Hepatology2014，，1： | 2 |
| 12 | American Gastroenterological Association Technical Review on the Management of Hepatitis C显示文摘 | Jules L. Dienstag John G. McHutchison | 2006 | Gastroenterology2006，，1： | 2 |
| 13 | P1232 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C INFECTION AFTER LIVER TRANSPLANTATION: RESULTS OF A PROSPECTIVE, MULTICENTER STUDY显示文摘 | D. Samuel M. Charlton E. Gane R. Brown M. Curry P. Kwo R. Fontana R. Gilroy L. Teperman A.J. Muir J.G. McHutchison W.T. Symonds J. Denning L. McNair S. Arterburn N. Terrault X. Forns M. Manns | 2014 | Journal of Hepatology2014，，1： | 2 |
| 14 | Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C显示文摘 | John G. McHutchison Michael Manns Keyur Patel Thierry Poynard Karen L. Lindsay Christian Trepo Jules Dienstag William M. Lee Carmen Mak Jean–Jacques Garaud Janice K. Albrecht | 2002 | Gastroenterology2002，，4： | 2 |
| 15 | The Course of Posttransplant Hepatitis C Infection: Comparative Impact of Donor and Recipient Source of the Favorable IL28B Genotype and Other Variables显示文摘 | Andres Duarte-Rojo Bart J. Veldt David D. Goldstein Hans L. Tillman Kymberly D. Watt Julie K. Heimbach John G. McHutchison John J. Poterucha Florencia Vargas-Vorackova Michael R. Charlton | 2012 | Transplantation Journal2012，，2： | 2 |
| 16 | Pegintefferon alfa - 2b plus ribavirin compared with interferon alfa - 2b plus ribavirin for initial treatment of chronic hepatitis C:a rancdomised trial显示文摘 | McHutchison JG Gordon SC | 2001 | 1ancet2001，358，： | 1 |
| 17 | Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:arandomised trial显示文摘 | Manns MP McHutchison JG Gordon SC | 2001 | Lancet2001，358，： | 1 |
| 18 | Peginterferon alpha-2b or alfa-2a with ribavirin for treatment of hepatitis C infection 显示文摘 | McHutchison JG Lawitz EJ Shiffman ML | 2009 | N Engl J Med2009，361，6： | 1 |
| 19 | Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients with Lamivudine-resistant Chronic Hepatitis B显示文摘 | Scott Fung Peter Kwan Milotka Fabri Andrzej Horban Mijomir Pelemis Hie-Won Hann Selim Gurel Florin A. Caruntu John F. Flaherty Benedetta Massetto Phillip Dinh Amoreena Corsa G. Mani Subramanian John G. McHutchison Petr Husa Edward Gane | 2013 | Gastroenterology2013，，： | 1 |
| 20 | New therapeutic strategies for hepatitis C显示文摘 | McHutchison J Rice CM | 2002 | Hepatology2002，35，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员